Sunil P.M.,Annamalai University |
Manikandhan R.,Meeanakshi Ammal Dental College |
Muthu M.S.,Saveetha Dental College |
Abraham S.,Nichi In Center for Regenerative Medicine
Journal of Oral and Maxillofacial Pathology
Cells with unique capacity for self-renewal and potency are called stem cells. With appropriate biochemical signals stem cells can be transformed into desirable cells. The idea behind this article is to shortly review the obtained literature on stem cell with respect to their properties, types and advantages of dental stem cells. Emphasis has been given to the possibilities of stem cell therapy in the oral and maxillofacial region including regeneration of tooth and craniofacial defects. Source
Raj R.,Oncology and Marrow Transplantation Unit |
Deenadayalan M.,Oncology and Marrow Transplantation Unit |
Vimal Kumar G.,Oncology and Marrow Transplantation Unit |
Khandelwal V.,Oncology and Marrow Transplantation Unit |
And 4 more authors.
Indian Journal of Hematology and Blood Transfusion
Advances in current treatment regimens in childhood acute lymphoblastic leukemia (ALL) have resulted in cure rates of 75–80 %. Some molecular genetic abnormalities confer a poor prognosis. Of these, the chromosomal translocation t (9;22)—Philadelphia chromosome is associated with the worst outcome in childhood ALL. Optimal therapy for this variant of ALL includes chemotherapy as per high risk schedule, imatinib and early stem cell transplantation. We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL. © 2014, Indian Society of Haematology & Transfusion Medicine. Source
Ratnavelu K.,Nilai Cancer Institute NCI Hospital |
Subramani B.,Nichi Asia Life science Sdn. Bhd |
Subramani B.,Acharya Nagarjuna University |
Pullai C.R.,Nichi Asia Life science Sdn. Bhd |
And 10 more authors.
Rare types of cancer are often not effectively treated by approaches such as chemotherapy and radiotherapy, although their side-effects persist. Immunotherapy has been gaining attention worldwide with growing examples of its anticancer activity demonstrated in vivo. This case report describes a 35-year-old male who suffered from advanced epithelioid sarcoma and underwent 18 cycles of chemotherapy without any significant response, who suffered adverse effects that caused lung collapse. A notable response was observed following the administration of autologous immune enhancement therapy (AIET), which involves a process of isolation, activation and expansion of natural killer (NK) and T cells, which were obtained from the patient's own (autologous) peripheral blood. With the present data and the response of the patient to AIET, it may be proposed that AIET is beneficial for patients suffering from advanced epithelioid sarcoma without producing adverse effects. Source
Parikumar P.,Light Eye Hospital |
Haraguchi K.,Kawamura Institute of Chemical Research |
Ohbayashi A.,Kawamura Institute of Chemical Research |
Senthilkumar R.,Nichi In Center for Regenerative Medicine |
And 3 more authors.
Current Eye Research
Purpose: In vitro expansion of human corneal endothelial precursor (HCEP) cells has been reported via production of cell aggregated spheres. However, to translate this procedure in human patients warrants maintaining the position of the eyeballs facing down for 36 h, which is not feasible. In this study, we report a method using a nanocomposite (NC) gel sheet to accomplish the integration of HCEP cells to the endothelium of cadaver bovine's eyes. Materials and Methods: HCEP cells were isolated from the corneal endothelium of a cadaver human eye and then expanded using a thermoreversible gelation polymer (TGP) as reported earlier. For the study, three cadaver bovine eyes were used. The NC gel sheets were inserted into the bovine eyes', aligned and suture-fixed in position under the host endothelium. HCEP cells previously expanded in the TGP were harvested and injected using a 26-gauge syringe between the endothelium and the NC gel sheet. The eyes were left undisturbed for three hours following which the NC gel sheets were gently removed. The corneas were harvested and subjected to histopathological studies. Results: Histopathological studies showed that all the three corneas used for NC gel sheet implantation showed the presence of engrafted HCEP cells, seen as multi-layered cells over the native endothelium of the bovine cornea. Examination of the NC gel sheets used for implantation showed that only very few corneal endothelial cells remained on the sheets amounting to what could be considered negligible. Conclusion: The use of the NC gel sheet makes HCEP cell transplantation feasible for human patients. Further in vitro basic studies followed by translational studies are necessary to bring this method for clinical application in appropriate indications. © Informa Healthcare USA, Inc. Source
Sankaranarayanan S.,Sree Moogambigai Dental College |
Sankaranarayanan S.,Mother Cell Regenerative Center |
Jetty N.,Thai Moogambigai Dental College |
Gadagi J.S.,Vishnu Dental College |
And 3 more authors.
Journal of Stem Cells
Regeneration of bony defects caused by periodontal disease continues to be a challenge for clinicians. Application of stem cells from different tissue sources and scaffolds for regeneration have been reported in animal models but clinical studies with long term follow-ups are limited. Herein we report the three years follow-up of the application of autologous bone marrow mononuclear cells (BMMNCs) embedded in a thermo-reversible gelation polymer (TGP) for periodontal regeneration. A 23-year female patient with advanced periodontitis (class IV gingival recession, probing pocket depth (PPD) of 5 mm and 6 mm in relation to mandibular lateral and central incisors respectively, and clinical attachment level (CAL) of 13 mm) correlated with radiographic evidence of severe horizontal bone loss extending up to the apex of mandibular incisors was selected for the treatment. After debridement, the defect was implanted with BMMNCs impregnated in TGP. Then the clinical parameters and radiographic evaluation were made at periodic intervals of 6, 12, 24 and 36 months. At six months, significant improvement with the clinical parameters (PPD had reduced to 2 mm, clinical attachment level had improved by 6 mm) was observed. At 36 months, the radiograph revealed bone regeneration with improvement in vertical and horizontal bone height. Transplantation of BMMNCs in a novel TGP is safe and results in a relatively significant and stable clinical outcome in horizontal alveolar bony defects. © Nova Science Publishers, Inc. Source